166 pending office actions • 11 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Hoffmann-La Roche, Inc. | 96 |
| Genentech, Inc. | 56 |
| Genentech, Inc. | 4 |
| Hoffmann-La Roche, Inc. | 2 |
| Roche Innovation Center Copenhagen A/S | 2 |
| Chugai Seiyaku Kabushiki Kaisha | 1 |
| Genentech Inc. | 1 |
| Roche Glycart AG | 1 |
| Ricc A/S | 1 |
| Roche Innovation Center Copenhagen A/S | 1 |
| Tmem16A Limited | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19418783 | Untitled | Genentech, Inc. | ALLEN, MARIANNE P | 1647 | Non-Final OA | |
| 19408114 | Untitled | Genentech, Inc. | SPENCE, JENNIFER SUZANNE | 1633 | Non-Final OA | |
| 19328820 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | Genentech, Inc. | AEDER, SEAN E | 1642 | Non-Final OA | Sep 15, 2025 |
| 19059186 | QUANTIFYING AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) IN ALZHEIMER'S PATIENTS | Hoffmann-La Roche, Inc. | MALDONADO, STEVEN | 3797 | Non-Final OA | Feb 20, 2025 |
| 19059182 | SEGMENTING AND DETECTING AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) IN ALZHEIMER'S PATIENTS | Hoffmann-La Roche, Inc. | GROSS, JASON PATRICK | 3797 | Non-Final OA | Feb 20, 2025 |
| 18888077 | MULTI-MODAL PATIENT REPRESENTATION | Hoffmann-La Roche, Inc. | MACCAGNO, PIERRE L | 3687 | Non-Final OA | Sep 17, 2024 |
| 18828915 | PHARMACEUTICAL ASSET TRACKING | Genentech, Inc. | BURSUM, KIMBERLY SUZANNE | 3627 | Non-Final OA | Sep 09, 2024 |
| 18779430 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | Hoffmann-La Roche, Inc. | YOO, SUN JAE | 1621 | Non-Final OA | Jul 22, 2024 |
| 18670375 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Hoffmann-La Roche, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | Non-Final OA | May 21, 2024 |
| 18669218 | SYNTHETIC CONTROLS FOR IMMUNOHISTOCHEMISTRY | Genentech, Inc. | NGUYEN, NAM P | 1678 | Final Rejection | May 20, 2024 |
| 18668774 | METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077 | Genentech, Inc. | BAEK, BONG-SOOK | 1611 | Non-Final OA | May 20, 2024 |
| 18645245 | Method for purifying PEGylated erythropoietin | Hoffmann-La Roche, Inc. | DEBERRY, REGINA M | 1647 | Non-Final OA | Apr 24, 2024 |
| 18644063 | SYSTEMS AND METHODS FOR ANALYSING DIGITAL IMAGES | Hoffmann-La Roche, Inc. | KRAYNAK, JACK PETER | 2668 | Non-Final OA | Apr 23, 2024 |
| 18627251 | BIOLOGICAL CONTEXT FOR ANALYZING WHOLE SLIDE IMAGES | Genentech, Inc. | ROSARIO, DENNIS | 2676 | Non-Final OA | Apr 04, 2024 |
| 18612987 | PIPELINES FOR TUMOR IMMUNOPHENOTYPING | Genentech, Inc. | VARNDELL, ROSS E | 2674 | Non-Final OA | Mar 21, 2024 |
| 18609853 | COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION | Hoffmann-La Roche, Inc. | SHIM, DAVID M. | 1626 | Non-Final OA | Mar 19, 2024 |
| 18606123 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | Hoffmann-La Roche, Inc. | INAM, SAHAR | 1622 | Non-Final OA | Mar 15, 2024 |
| 18590606 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | Hoffmann-La Roche, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | Non-Final OA | Feb 28, 2024 |
| 18584298 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | Genentech, Inc. | MOORE, SUSANNA | 1624 | Non-Final OA | Feb 22, 2024 |
| 18584311 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | Genentech, Inc. | YOO, SUN JAE | 1621 | Non-Final OA | Feb 22, 2024 |
| 18443690 | OBJECT RECONSTRUCTION IN DIGITAL IMAGES | Hoffmann-La Roche, Inc. | LANTZ, KARSTEN FOSTER | 2664 | Non-Final OA | Feb 16, 2024 |
| 18441878 | E3 UBIQUITIN LIGASE (UBE3A) PROTEIN TARGETS | Hoffmann-La Roche, Inc. | SELWANES, JOHN PAUL | 1651 | Non-Final OA | Feb 14, 2024 |
| 18430887 | METHOD FOR DETERMINING THE AMOUNT OF A THERAPEUTIC ANTIBODY IN THE BRAIN | Hoffmann-La Roche, Inc. | HUYNH, PHUONG N | 1641 | Non-Final OA | Feb 02, 2024 |
| 18294059 | ORGAN IDENTIFICATION USING AI | Hoffmann-La Roche, Inc. | SHIFERAW, HENOK ASRES | 2676 | Non-Final OA | Jan 31, 2024 |
| 18389809 | MULTISTEP FINAL FILTRATION | Hoffmann-La Roche, Inc. | PAK, YONG D | 1652 | Non-Final OA | Dec 20, 2023 |
| 18545711 | PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS | Hoffmann-La Roche, Inc. | JACKSON, SHAWQUIA | 1626 | Non-Final OA | Dec 19, 2023 |
| 18542088 | SPATIAL ANALYSIS OF MITOTIC FIGURES IN HISTOPATHOLOGICAL IMAGES | Hoffmann-La Roche, Inc. | AUGUSTIN, MARCELLUS | 2682 | Final Rejection | Dec 15, 2023 |
| 18540310 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. | DEKARSKE, MADELINE MCGUIRE | 1622 | Non-Final OA | Dec 14, 2023 |
| 18533710 | SOLID FORMS OF (3R)-N-[2-CYANO-4-FLUORO-3-(3-METHYL-4-OXO-QUINAZOLIN-6-YL)OXY-PHENYL]-3-FLUORO-PYRROLIDINE-1-SULFONAMIDE | Hoffmann-La Roche, Inc. | HSU, GRACE CHING | 1627 | Non-Final OA | Dec 08, 2023 |
| 18533622 | METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A MEK INHIBITOR | Chugai Seiyaku Kabushiki Kaisha | NESTOR, DONNA MICHELLE | 1627 | Non-Final OA | Dec 08, 2023 |
| 18525536 | METHYLQUINAZOLINONE DERIVATIVES | Hoffmann-La Roche, Inc. | MCKOY, QUINCY ANDRE | 1626 | Non-Final OA | Nov 30, 2023 |
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | Genentech, Inc. | SHIAO, REI TSANG | 1691 | Non-Final OA | Nov 29, 2023 |
| 18519529 | PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS | Genentech, Inc. | HAVLIN, ROBERT H | 1626 | Non-Final OA | Nov 27, 2023 |
| 18518715 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | Genentech, Inc. | PENNINGTON, HALLIE NICOLE | 1671 | Non-Final OA | Nov 24, 2023 |
| 18517468 | METHOD FOR PRODUCING AN IMMUNOCONJUGATE | Hoffmann-La Roche, Inc. | LEONARD, ARTHUR S | 1631 | Non-Final OA | Nov 22, 2023 |
| 18516406 | DETECTING TERTIARY LYMPHOID STRUCTURES IN DIGITAL PATHOLOGY IMAGES | Genentech, Inc. | HOANG, HAN DINH | 2661 | Non-Final OA | Nov 21, 2023 |
| 18516417 | TUMOR IMMUNOPHENOTYPING BASED ON SPATIAL DISTRIBUTION ANALYSIS | Genentech, Inc. | HOANG, HAN DINH | 2661 | Non-Final OA | Nov 21, 2023 |
| 18516014 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | Non-Final OA | Nov 21, 2023 |
| 18514478 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | Hoffmann-La Roche, Inc. | DAHLIN, HEATHER RAQUEL | 1629 | Non-Final OA | Nov 20, 2023 |
| 18510227 | COMBINATION THERAPY | Genentech, Inc. | LEE, CHIHYI NMN | 1628 | Non-Final OA | Nov 15, 2023 |
| 18499759 | TRIFAB-CONTORSBODY | Hoffmann-La Roche, Inc. | HUYNH, PHUONG N | 1641 | Final Rejection | Nov 01, 2023 |
| 18491669 | PREVENTION OR MITIGATION OF NK CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | Hoffmann-La Roche, Inc. | NICKOL, GARY B | 1643 | Non-Final OA | Oct 20, 2023 |
| 18380141 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche, Inc. | JAIPRASHAD, RAJESH | 1691 | Non-Final OA | Oct 13, 2023 |
| 18479596 | PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS | Hoffmann-La Roche, Inc. | NESTOR, DONNA MICHELLE | 1627 | Non-Final OA | Oct 02, 2023 |
| 18469957 | METHODS OF TREATING LUNG CANCER WITH A PD-1 AXIS BINDING ANTAGONIST, AN ANTIMETABOLITE, AND A PLATINUM AGENT | Genentech, Inc. | TAYLOR, LIA ELAN | 1641 | Non-Final OA | Sep 19, 2023 |
| 18468356 | THIENOPYRIMIDINONE DERIVATIVES | Hoffmann-La Roche, Inc. | CHEN, PO-CHIH | 1621 | Non-Final OA | Sep 15, 2023 |
| 18369140 | PROCESS | Hoffmann-La Roche, Inc. | HAVLIN, ROBERT H | 1626 | Non-Final OA | Sep 15, 2023 |
| 18465854 | COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS | Hoffmann-La Roche, Inc. | HOLTZMAN, KATHERINE ANN | 1646 | Non-Final OA | Sep 12, 2023 |
| 18464580 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | Genentech, Inc. | SHUPE, ELIZABETH A | 1643 | Non-Final OA | Sep 11, 2023 |
| 18463585 | ATTENTION-BASED MULTIPLE INSTANCE LEARNING FOR WHOLE SLIDE IMAGES | Genentech, Inc. | TRAN, DUY ANH | 2674 | Final Rejection | Sep 08, 2023 |
| 18459135 | NOVEL BIOMARKERS AND USES THEREOF | Hoffmann-La Roche, Inc. | CHHAY, BONIRATH | 1645 | Non-Final OA | Aug 31, 2023 |
| 18331536 | Novel Synthesis of Phosphorodithioate Oligonucleotides | Hoffmann-La Roche, Inc. | LAU, JONATHAN S | 1693 | Non-Final OA | Aug 29, 2023 |
| 18457729 | BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP | Hoffmann-La Roche, Inc. | AEDER, SEAN E | 1642 | Non-Final OA | Aug 29, 2023 |
| 18455029 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | Hoffmann-La Roche, Inc. | COUGHLIN, MATTHEW P | 1626 | Non-Final OA | Aug 24, 2023 |
| 18454315 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | GAUGER, PAUL RANDALL | 1629 | Non-Final OA | Aug 23, 2023 |
| 18449807 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND IPATASERTIB | Genentech, Inc. | CHAO, ALLEN | 1622 | Non-Final OA | Aug 15, 2023 |
| 18449800 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND GDC-0077 | Genentech, Inc. | RZECZYCKI, PHILLIP MATTHEW | 1625 | Non-Final OA | Aug 15, 2023 |
| 18449862 | PROCESS FOR THE DE-TRITYLATION OF OLIGONUCLEOTIDES | Hoffmann-La Roche, Inc. | OLSON, ANDREA STEFFEL | 1693 | Non-Final OA | Aug 15, 2023 |
| 18546087 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | Hoffmann-La Roche, Inc. | HABTE, KAHSAY | 1624 | Non-Final OA | Aug 10, 2023 |
| 18275655 | AMIDES AS CBL-B INHIBITORS | Genentech, Inc. | SEITZ, ANTHONY JOSEPH | 1629 | Non-Final OA | Aug 03, 2023 |
| 18364185 | ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF | Genentech, Inc. | ALLEN, MARIANNE P | 1647 | Final Rejection | Aug 02, 2023 |
| 18357772 | PATHOLOGICAL RESPONSE CALCULATION AND ASSESSMENT TOOL | Genentech, Inc. | WALLACE, JOHN R | 2682 | Non-Final OA | Jul 24, 2023 |
| 18347362 | COMBINATION THERAPY EMPLOYING A PD1-LAG3 BISPECIFIC ANTIBODY AND A CD20 T CELL BISPECIFIC ANTIBODY | Hoffmann-La Roche, Inc. | STEIN, LEAH ELIZABETH | 1641 | Non-Final OA | Jul 05, 2023 |
| 18346128 | ANTI-CD8 ANTIBODIES AND USES THEREOF | Genentech, Inc. | SLOUP IV, RUDOLPH EDWARD | 1645 | Non-Final OA | Jun 30, 2023 |
| 18335515 | PRECURSOR PROTEINS AND KIT FOR TARGETED THERAPY | Hoffmann-La Roche, Inc. | REDDIG, PETER J | 1646 | Non-Final OA | Jun 15, 2023 |
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | Genentech, Inc. | HUYNH, PHUONG N | 1641 | Final Rejection | Jun 15, 2023 |
| 18208029 | POLYMERS AND USES THEREOF | Hoffmann-La Roche, Inc. | BASQUILL, SEAN M | 1614 | Non-Final OA | Jun 09, 2023 |
| 18256629 | Process for the preparation of 4-(3,5-difluorophenyl)-N-[3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine | Hoffmann-La Roche, Inc. | WILLIS, DOUGLAS M | 1624 | Non-Final OA | Jun 08, 2023 |
| 18204281 | INDUCTIVE HEAT STERILIZING SYSTEMS, DEVICES, AND METHODS | Genentech, Inc. | LEE, AHAM NMN | 1758 | Non-Final OA | May 31, 2023 |
| 18255076 | NEW INDAZOLE DERIVATIVES | Hoffmann-La Roche, Inc. | DAHLIN, HEATHER RAQUEL | 1629 | Non-Final OA | May 30, 2023 |
| 18201904 | METHODS FOR PREPARING MAMMALIAN CELLS FOR PERFUSION CELL CULTURE | Genentech, Inc. | MONTANARI, DAVID A | 1632 | Non-Final OA | May 25, 2023 |
| 18321199 | CONTAINED SINGLE-USE POWDER INDUCTION SYSTEM AND METHOD OF USE | Genentech, Inc. | BHATIA, ANSHU | 1774 | Non-Final OA | May 22, 2023 |
| 18319920 | AROMATIC BRIDGED RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | SAEED, KAMAL A | 1626 | Non-Final OA | May 18, 2023 |
| 18319860 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | COLEMAN, BRENDA LIBBY | 1624 | Non-Final OA | May 18, 2023 |
| 18319618 | Reusable Cartridges for Detecting Analytes in Solution | Genentech Inc. | MONTGOMERY, ANN Y | 1678 | Non-Final OA | May 18, 2023 |
| 18319895 | AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | COLEMAN, BRENDA LIBBY | 1624 | Non-Final OA | May 18, 2023 |
| 18318914 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | COLEMAN, BRENDA LIBBY | 1624 | Non-Final OA | May 17, 2023 |
| 18318947 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | Hoffmann-La Roche, Inc. | HAVLIN, ROBERT H | 1626 | Non-Final OA | May 17, 2023 |
| 18318144 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | DAHLIN, HEATHER RAQUEL | 1629 | Non-Final OA | May 16, 2023 |
| 18318466 | COMBINATION THERAPY WITH FAP-TARGETED CD40 AGONISTS | Hoffmann-La Roche, Inc. | KAUFMAN, CLAIRE M | 1674 | Non-Final OA | May 16, 2023 |
| 18195134 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | Genentech, Inc. | WILSON, JERICA KATLYNN | 1621 | Non-Final OA | May 09, 2023 |
| 18303802 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | Hoffmann-La Roche, Inc. | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Apr 20, 2023 |
| 18303451 | PRODUCTION CELLS | Hoffmann-La Roche, Inc. | MOAZZAMI, NAGHMEH NINA | 1652 | Non-Final OA | Apr 19, 2023 |
| 18301169 | ANTI-CLEAVED ICASPASE SUBSTRATE ANTIBODIES AND METHODS OF USE | Genentech, Inc. | TAYLOR, LIA ELAN | 1641 | Non-Final OA | Apr 14, 2023 |
| 18297546 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | Genentech, Inc. | JARRELL, NOBLE E | 1699 | Final Rejection | Apr 07, 2023 |
| 18297553 | STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS | Genentech, Inc. | KIM, YUNSOO | 1641 | Non-Final OA | Apr 07, 2023 |
| 18194542 | HYDROXYPROPYL METHYL CELLULOSE DERIVATIVES TO STABILIZE POLYPEPTIDES | Genentech, Inc. | KNIGHT, SAMANTHA JO | 1614 | Non-Final OA | Mar 31, 2023 |
| 18194423 | PROCESS FOR THE PREPARATION OF BIHETEROARYL COMPOUNDS AND CRYSTAL FORMS THEREOF | Hoffmann-La Roche, Inc. | RICCI, CRAIG D | 1611 | Non-Final OA | Mar 31, 2023 |
| 18186783 | ANTI-TIM3 ANTIBODIES AND METHODS OF USE | Hoffmann-La Roche, Inc. | BRISTOL, LYNN ANNE | 1643 | Non-Final OA | Mar 20, 2023 |
| 18245372 | RESULTS OF EMPACTA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIA | Genentech, Inc. | DEVI, SARVAMANGALA | 1645 | Non-Final OA | Mar 15, 2023 |
| 18180977 | ANTI-CEA ANTIBODIES | Roche Glycart AG | ALLEN, MARIANNE P | 1647 | Non-Final OA | Mar 09, 2023 |
| 18178874 | COMBINATION THERAPY OF TUMOR TARGETED ICOS AGONISTS WITH T-CELL BISPECIFIC MOLECULES | Hoffmann-La Roche, Inc. | SKELDING, ZACHARY S | 1644 | Non-Final OA | Mar 06, 2023 |
| 18117966 | NOVEL HETEROCYCLIC COMPOUNDS | Hoffmann-La Roche, Inc. | MCDOWELL, BRIAN E | 1624 | Non-Final OA | Mar 06, 2023 |
| 18176062 | CRISPR/Cas9 MULTIPLEX KNOCKOUT OF HOST CELL PROTEINS | Hoffmann-La Roche, Inc. | FLINDERS, JEREMY C | 1684 | Non-Final OA | Feb 28, 2023 |
| 18173673 | POINT OF CARE DRUG DELIVERY APPARATUS AND METHOD | Genentech, Inc. | STIGELL, THEODORE J | 3783 | Non-Final OA | Feb 23, 2023 |
| 18171130 | USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | HUDSON, AMY ROSE | 1636 | Non-Final OA | Feb 17, 2023 |
| 18163819 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | Genentech, Inc. | CASH, KAILEY ELIZABETH | 1683 | Non-Final OA | Feb 02, 2023 |
| 18162508 | ANTIGEN BINDING RECEPTORS | Hoffmann-La Roche, Inc. | PETERS, ALEC JON | 1641 | Non-Final OA | Jan 31, 2023 |
| 18103679 | METHODS FOR TREATING EXACERBATIONS OF INFLAMMATORY RESPIRATORY DISEASES | Hoffmann-La Roche, Inc. | BERKE-SCHLESSEL, DAVID W | 1651 | Non-Final OA | Jan 31, 2023 |
| 18157286 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES | Hoffmann-La Roche, Inc. | SAMSELL, RILLA MARIE | 1624 | Non-Final OA | Jan 20, 2023 |
| 18156744 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | Genentech, Inc. | VAN DRUFF, SYDNEY | 1643 | Non-Final OA | Jan 19, 2023 |
| 18153234 | ASSAYS FOR FIXED DOSE COMBINATIONS | Hoffmann-La Roche, Inc. | CHEU, CHANGHWA J | 1678 | Non-Final OA | Jan 11, 2023 |
| 18150553 | Process for the preparation of oligonucleotides using modified oxidation protocol | Hoffmann-La Roche, Inc. | LAU, JONATHAN S | 1693 | Non-Final OA | Jan 05, 2023 |
| 18150466 | ALTERNATIVE SURFACTANTS AS STABILIZERS FOR THERAPEUTIC PROTEIN FORMULATIONS | Hoffmann-La Roche, Inc. | CHEONG, CHEOM-GIL | 1645 | Final Rejection | Jan 05, 2023 |
| 18079729 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | Hoffmann-La Roche, Inc. | SHAMEEM, GOLAM M | 1621 | Non-Final OA | Dec 12, 2022 |
| 18001098 | Guanosine Analogues for Use in Therapeutics Polynucleotides | Ricc A/S | VANHORN, ABIGAIL LOUISE | 1636 | Non-Final OA | Dec 08, 2022 |
| 18076383 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | Hoffmann-La Roche, Inc. | WILLIS, DOUGLAS M | 1624 | Final Rejection | Dec 06, 2022 |
| 18076274 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | Hoffmann-La Roche, Inc. | HSU, GRACE CHING | 1627 | Non-Final OA | Dec 06, 2022 |
| 17986101 | Oligonucleotide Agonists Targeting Progranulin | Hoffmann-La Roche, Inc. | CHONG, KIMBERLY | 1636 | Non-Final OA | Nov 14, 2022 |
| 18054116 | COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME | Genentech, Inc. | CHONG, KIMBERLY | 1636 | Non-Final OA | Nov 09, 2022 |
| 17982361 | HIGH IONIC STRENGTH DISSOCIATION ASSAY FOR HIGH DRUG TOLERANT TESTING | Hoffmann-La Roche, Inc. | GABEL, GAILENE | 1678 | Non-Final OA | Nov 07, 2022 |
| 18052113 | TRANSGENIC RABBIT WITH COMMON LIGHT CHAIN | Hoffmann-La Roche, Inc. | WILSON, MICHAEL C | 1638 | Non-Final OA | Nov 02, 2022 |
| 18051307 | PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS | Hoffmann-La Roche, Inc. | BRISTOL, LYNN ANNE | 1643 | Final Rejection | Oct 31, 2022 |
| 17976651 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | Hoffmann-La Roche, Inc. | COUGHLIN, MATTHEW P | 1626 | Final Rejection | Oct 28, 2022 |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | Genentech, Inc. | GODDARD, LAURA B | 1642 | Non-Final OA | Oct 24, 2022 |
| 17996338 | IMMUNOCONJUGATES | Hoffmann-La Roche, Inc. | HOPKINS, SAMANTHA LAKE | 1641 | Non-Final OA | Oct 14, 2022 |
| 18046865 | METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES | Genentech, Inc. | SKELDING, ZACHARY S | 1644 | Non-Final OA | Oct 14, 2022 |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | Genentech, Inc. | MOSS, NATALIE M | 1653 | Non-Final OA | Oct 12, 2022 |
| 18045037 | LARGE MOLECULE UNSPECIFIC CLEARANCE ASSAY | Hoffmann-La Roche, Inc. | SVEIVEN, MICHAEL CAMERON | 1678 | Final Rejection | Oct 07, 2022 |
| 17822746 | EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS | Genentech, Inc. | VANHORN, ABIGAIL LOUISE | 1636 | Non-Final OA | Aug 26, 2022 |
| 17821425 | SPR-based dual-binding assay for the functional analysis of multispecific molecules | Hoffmann-La Roche, Inc. | DUNN, MCKENZIE A | 1678 | Final Rejection | Aug 22, 2022 |
| 17819064 | CD40L EXPRESSING MAMMALIAN CELLS AND THEIR USE | Hoffmann-La Roche, Inc. | ZHU, JIANJIAN | 1631 | Final Rejection | Aug 11, 2022 |
| 17817925 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Hoffmann-La Roche, Inc. | HECK, BRYAN WILLIAM | 1643 | Non-Final OA | Aug 05, 2022 |
| 17869755 | NOVEL HETEROCYCLIC COMPOUNDS | Hoffmann-La Roche, Inc. | MCDOWELL, BRIAN E | 1624 | Non-Final OA | Jul 20, 2022 |
| 17811376 | 4-1BBL TRIMER-CONTAINING ANTIGEN BINDING MOLECULES | Hoffmann-La Roche, Inc. | MARVICH, MARIA | 1634 | Final Rejection | Jul 08, 2022 |
| 17810287 | ADA-RESPONSE SPECIFICATION ASSAY | Hoffmann-La Roche, Inc. | DUFFY, BRADLEY | 1643 | Final Rejection | Jun 30, 2022 |
| 17845535 | USE OF SARAF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | MEYERING, SHABANA SHABBEER | 1635 | Non-Final OA | Jun 21, 2022 |
| 17845178 | USE OF SCAMP3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Non-Final OA | Jun 21, 2022 |
| 17845592 | USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | SULLIVAN, STEPHANIE LAUREN | 1635 | Non-Final OA | Jun 21, 2022 |
| 17845311 | USE OF SBDS INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Hoffmann-La Roche, Inc. | PERSONS, JENNA L | 1637 | Non-Final OA | Jun 21, 2022 |
| 17845960 | EXTENDED REALITY SYSTEM TO TREAT SUBJECTS ASSOCIATED WITH AUTISM SPECTRUM DISORDER | Hoffmann-La Roche, Inc. | MATTHEWS, CHRISTINE HOPKINS | 3791 | Non-Final OA | Jun 21, 2022 |
| 17842715 | CULTURE SYSTEM AND METHODS FOR IMPROVED MODELING OF NEUROLOGICAL CONDITIONS | Genentech, Inc. | TRAN, KHOA NHAT | 1632 | Final Rejection | Jun 16, 2022 |
| 17835261 | BRAF INHIBITORS AS PARADOX BREAKERS | Hoffmann-La Roche, Inc. | MAHLUM, JONATHAN DAVIS | 1625 | Non-Final OA | Jun 08, 2022 |
| 17780127 | PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | Hoffmann-La Roche, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | Non-Final OA | May 26, 2022 |
| 17804072 | METHOD FOR PRODUCING MULTISPECIFIC ANTIBODIES | Hoffmann-La Roche, Inc. | RAGHU, GANAPATHIRAM | 1652 | Final Rejection | May 25, 2022 |
| 17721798 | METHOD FOR THE SELECTION OF A LONG-TERM PRODUCING CELL USING HISTONE ACYLATION AS MARKERS | Hoffmann-La Roche, Inc. | LEITH, NANCY J | 1636 | Non-Final OA | Apr 15, 2022 |
| 17720676 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | Roche Innovation Center Copenhagen A/S | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Non-Final OA | Apr 14, 2022 |
| 17700987 | FLUORESCENT PROBES FOR MONOACYLGLYCEROL LIPASE (MAGL) | Hoffmann-La Roche, Inc. | YOUNG, MICAH PAUL | 1618 | Non-Final OA | Mar 22, 2022 |
| 17665144 | PERSONALIZED TREATMENT OF OPHTHALMOLOGIC DISEASES | Genentech, Inc. | DARPOLOR, JOSEPHINE KEBBEH | 1642 | Non-Final OA | Feb 04, 2022 |
| 17581504 | PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS | Tmem16A Limited | ENGLISH, CONNOR KENNEDY | 1625 | Non-Final OA | Jan 21, 2022 |
| 17629327 | DETECTING NEURALLY PROGRAMMED TUMORS USING EXPRESSION DATA | Genentech, Inc. | MINCHELLA, KAITLYN L | 1685 | Final Rejection | Jan 21, 2022 |
| 17616930 | ALTERNATIVE PROCESS FOR THE PREPARATION OF 4-PHENYL-5-ALKOXYCARBONYL-2-THIAZOL-2-YL-1,4-DIHYDROPYRIMIDIN-6-YL]METHYL]-3-OXO-5,6,8,8A-TETRAHYDRO-1H-IMIDAZO[1,5-A]PYRAZIN-2-YL]-CARBOXYLIC ACID | Hoffmann-La Roche, Inc. | WILSON, JERICA KATLYNN | 1621 | Final Rejection | Dec 06, 2021 |
| 17542138 | METHOD FOR REGENERATION OF AN OVERLOAD CHROMATOGRAPHY COLUMN | Genentech, Inc. | KIM, YUNSOO | 1641 | Non-Final OA | Dec 03, 2021 |
| 17513710 | PURIFICATION PLATFORMS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS HAVING A REDUCED HYDROLYTIC ENZYME ACTIVITY RATE | Genentech, Inc. | SUNSHINE, HANNAH LOUISE | 1647 | Non-Final OA | Oct 28, 2021 |
| 17507029 | THERAPEUTIC MULTISPECIFIC POLYPEPTIDES ACTIVATED BY POLYPEPTIDE CHAIN EXCHANGE | Hoffmann-La Roche, Inc. | HUYNH, PHUONG N | 1641 | Final Rejection | Oct 21, 2021 |
| 17507511 | ACTIVATABLE THERAPEUTIC MULTISPECIFIC POLYPEPTIDES WITH EXTENDED HALF-LIFE | Hoffmann-La Roche, Inc. | HUYNH, PHUONG N | 1641 | Final Rejection | Oct 21, 2021 |
| 17503122 | ANTIBODY POTENCY ASSAY | Genentech, Inc. | EVANS, CHRISTOPHER RYAN | 1677 | Non-Final OA | Oct 15, 2021 |
| 17500774 | NUCLEIC ACID CONSTRUCTS FOR SIMULTANEOUS GENE ACTIVATION | Hoffmann-La Roche, Inc. | KONOPKA, CATHERINE ANNE | 1635 | Non-Final OA | Oct 13, 2021 |
| 17497633 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | Hoffmann-La Roche, Inc. | BURKETT, DANIEL JOHN | 1624 | Final Rejection | Oct 08, 2021 |
| 17469533 | METHODS FOR DETECTING AND QUANTIFYING MEMBRANE-ASSOCIATED PROTEINS | Genentech, Inc. | COOK, LISA V | 1642 | Final Rejection | Sep 08, 2021 |
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | Genentech, Inc. | BAILEY, STEVEN WILLIAM | 1687 | Non-Final OA | Jul 16, 2021 |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | Genentech, Inc. | GODDARD, LAURA B | 1642 | Final Rejection | Jun 18, 2021 |
| 17343543 | MODIFIED ANTIBODY FCS AND METHODS OF USE | Genentech, Inc. | GUSTILO, ESTELLA M | 1646 | Non-Final OA | Jun 09, 2021 |
| 17335702 | AFFINITY CHROMATOGRAPHY PURIFICATION WITH LOW CONDUCTIVITY WASH BUFFER | Hoffmann-La Roche, Inc. | HUYNH, PHUONG N | 1641 | Final Rejection | Jun 01, 2021 |
| 17335680 | Method for the reduction of host cell proteins in affinity chromatography | Hoffmann-La Roche, Inc. | KIM, YUNSOO | 1641 | Final Rejection | Jun 01, 2021 |
| 17229746 | COPPER LOSS MITIGATION | Genentech, Inc. | MIANO, JOSEPH PAUL | 1631 | Non-Final OA | Apr 13, 2021 |
| 17249457 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | Genentech, Inc. | KENYON, JOHN S | 1625 | Final Rejection | Mar 02, 2021 |
| 17271491 | NEOANTIGEN ENGINEERING USING SPLICE MODULATING COMPOUNDS | Roche Innovation Center Copenhagen A/S | SULLIVAN, DENNIS JOHN | 1642 | Non-Final OA | Feb 25, 2021 |
| 17172528 | CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION | Genentech, Inc. | AFREMOVA, VERA | 1653 | Final Rejection | Feb 10, 2021 |
| 17264790 | OLIGONUCLEOTIDES COMPRISING A PHOSPHOROTRITHIOATE INTERNUCLEOSIDE LINKAGE | Roche Innovation Center Copenhagen A/S | VYAS, KEYUR ANILKUMAR | 1637 | Final Rejection | Jan 29, 2021 |
| 17111820 | PEPTIDIC LINKER WITH REDUCED POST-TRANSLATIONAL MODIFICATION | Hoffmann-La Roche, Inc. | DUTT, ADITI | 1675 | Non-Final OA | Dec 04, 2020 |
| 17080505 | Methods for purification of polypeptides using polysorbates | Hoffmann-La Roche, Inc. | REGLAS, GEORGIANA C | 1651 | Final Rejection | Oct 26, 2020 |
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | Genentech, Inc. | STONEBRAKER, ALYSSA RAE | 1642 | Non-Final OA | Oct 20, 2020 |
| 17017576 | THERAPEUTIC COMBINATION OF 4-1 BB AGONISTS WITH ANTI-CD20 ANTIBODIES | Hoffmann-La Roche, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | Final Rejection | Sep 10, 2020 |
| 16906937 | METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELLS BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION | Hoffmann-La Roche, Inc. | SPENCE, JENNIFER SUZANNE | 1633 | Final Rejection | Jun 19, 2020 |
| 16221369 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | Genentech, Inc. | HALVORSON, MARK | 1646 | Non-Final OA | Dec 14, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial